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ABSTRACT
Objective: Many people who have severe chronic kidney disease (CKD) will eventually develop kidney failure and will require dialysis. The control 
of parathormone (PTH), phosphorus, and calcium metabolism is one of the objectives in an adequate dialysis protocol. Therefore, we conducted 
this study to describe alterations in PTH, calcium, and phosphorous homeostasis in patients with CKD on hemodialysis in our center. Our study also 
aimed to find an association between hormonal and biochemical abnormalities in CKD patients, who have been on hemodialysis for ≥5 months and 
comparing the results obtained with that recommended by Kidney Disease Improving Global Outcomes (KDIGO) guidelines.
Methods: This was a hospital-based cross-sectional observational study. The study population of 330 patients (>18 years) on maintenance 
hemodialysis coming to dialysis Unit of Department of Medicine of Gian Sagar Hospital, Ramnagar (Patiala), over a period of 3 years (2012-2015), 
were enrolled in the study. Each patient was considered only once for the study. In addition, biochemical analysis of serum intact PTH (iPTH), corrected 
calcium, phosphorus, total alkaline phosphatase (tALP), serum creatinine, blood urea, serum albumin, and hemoglobin of all cases was done using 
fully automated equipment. All statistical analyses were performed using SPSS statistical software, version 17.
Results: The study population of 330 patients comprised adults, mainly illiterate (54.5%) predominantly belonging to the rural (66.4%) strata with 
a mean age of 52.67±15.05 (range: 25-98 years). The abnormality in the laboratory profile of the patients was found to be hyperparathyroidism in 
40.3% as compared to hypoparathyroidism in 33.5% and normal iPTH levels in 26.2%. Hypocalcaemia was detected in 50.6% and hyperphosphatemia 
in 62.1% of the patients. There was statistically significant association of serum iPTH, with corrected calcium and phosphorus  (P=0.032 and P=0.035, 
respectively). Corrected calcium was also significantly associated with phosphorus (P=0.001) and tALP (P=0.007).
Conclusion: We showed in the present study that disorders of mineral metabolism are common in hemodialysis patients and that only a small 
proportion adheres to the targets as advised in the KDIGO guidelines for bone metabolism and disease in CKD. We demonstrated that these disorders 
are associated with important negative clinical outcomes, such as increased all-cause lack survival, more muscle and bone problems. Our findings, 
therefore, support a strict control of mineral metabolism in dialysis patients. Further research and progress in this area are required to establish a 
more rational approach with a view toward improving patient outcomes.
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INTRODUCTION
Calcium and phosphorus are minerals that are of great importance for 
the composition of bones and the regulation of several processes in 
the body [1]. The kidney plays a leading role in maintaining calcium 
and phosphorus homeostasis in collaboration with other organs, 
i.e., the parathyroid gland, intestines, and bones. Thus, along with the 
progression of chronic kidney disease (CKD), various abnormalities 
of mineral and bone metabolism develop such as hyperphosphatemia, 
hypocalcemia [2], and CKD has a negative effect on parathyroid 
gland, associated with an increased risk of PTH, namely secondary 
hyperparathyroidism [3]. These are commonly observed alterations in 
patients with CKD which can result in significant consequences [2].
Alterations in the control mechanisms for calcium and phosphorus 
homeostasis occur early in the course of CKD and progress as kidney 
functions deteriorate; if left untreated, these alterations can result in 
significant consequences, making disturbances of bone and mineral 
metabolism a hallmark of CKD [4].
Disturbances in mineral metabolism in CKD which result in multisystem 
disorder have now been given a different identity as CKD-MBD (CKD-
mineral and bone disorder) by Kidney Disease Improving Global 
Outcomes (KDIGO) 2009 [5]. The KDIGO is an international initiative 
with a key mission of developing evidence-based clinical practice 
guidelines for the prevention, diagnosis, evaluation, and treatment of 
CKD and has added “MBD to CKD to be now called as CKD-MBD” [6]. 
It has been an area of intense interest and as well as controversy [7].
CKD-MBD, the new terminology used for renal osteodystrophy and 
renal bone disease, is essentially a broad clinical disorder which is a 
manifestation of any one or combination of various abnormalities in 
clinical setting as follows:
• Abnormalities of biochemical parameters (calcium, phosphorus, 
parathyroid hormone).
• Intact parathormone (iPTH) and Vitamin D metabolism.
• Abnormalities in bone turnover, mineralization, volume, linear 
growth, or strength.
• Calcification of the vasculature or other soft tissues [5].
These are closely inter-related and together make major contribution to 
morbidity and mortality of patients with CKD receiving dialysis [8]. The 
KDIGO [5] for bone metabolism and disease in CKD (USA) recommend 
that, in stage 5 CKD, the target levels for calcium (Ca) (corrected for 
serum albumin), phosphorus (P), calcium × phosphorus (Ca × P) 
product, and PTH levels should be maintained at 8.5-10.5 mg/dl, 
2.5-4.5 mg/dl, <55 mg2/dl2, and 100-300 pg/ml, respectively.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Many people who have severe CKD will eventually develop kidney 
failure and will require dialysis. Despite remarkable advances in the 
technical ability to provide maintenance dialysis, the mortality rate 
of patients on long-term dialysis has remained unacceptably high and 
not significantly improved over the past decade. The control of PTH, 
phosphorus, and calcium metabolism is one of the objectives in an 
adequate dialysis protocol.
At present, there is more stress on calcium, phosphorus, and other 
minerals for regular monitoring in dialysis patients, but the aim of 
the treatment must be control of phosphate retention, maintaining 
serum calcium concentration within the normal range (standard), with 
avoidance of hypercalcemia and prevention of excess PTH secretion. 
PTH levels should be evaluated regularly in hemodialysis patients, and 
awareness regarding PTH abnormalities should be there among the 
treating physicians also.
Furthermore, estimation of PTH was used as the main biochemical 
indicator along with calcium and phosphorus as compared to previous 
studies which only stress upon mineral (Ca and P) derangements in 
patients with CKD.
Therefore, we conducted this study to describe alterations in PTH, 
calcium, and phosphorous homeostasis in patients with CKD on 
hemodialysis in our center. Our study also aimed to find an association 
between hormonal and biochemical abnormalities in patients 
with CKD, who have been on hemodialysis for ≥5 months in the dialysis 
unit at Gian Sagar hospital, and comparing the results obtained with 
that recommended by the KDIGO guidelines.
CKD-MBD still remains a major problem; hence, improving the ways 
of detection is the key to tackling this issue, so this study might help 




This study was a hospital-based, cross-sectional, observational study.
Research setting and participants
The study was conducted in the Department of Physiology of Gian 
Sagar Medical College and Hospital, in close collaboration with Dialysis 
Unit-Department of Medicine and Department of Biochemistry. The 
study was based on data collected on patients coming to dialysis unit 
of Department of Medicine, Gian Sagar Medical Hospital, Ramnagar, 
Patiala.
All the CKD patients on maintenance hemodialysis coming to Dialysis 
Unit of Department of Medicine of Gian Sagar Medical College 
and Hospital, Ramnagar (Patiala), over a period of 3 years from 
December, 2012, to December, 2015 (total enrolled patients - 330), 
were enrolled in this study. Each patient was considered only once for 
the study. Non-random sampling method was used in this study.
Ethical approval and informed consent
This study was approved by the Ethical Committee of Gian Sagar 
Medical College and Hospital. Informed consent was obtained from 
all the patients before the initiation the study. All the patients were 
duly informed about the purpose of asking questions as per pro forma 
attached with consent form, details of blood sample collection, risk 
factors, and precautions.
Inclusion criteria
All the patients (>18 years) on maintenance hemodialysis coming to 
dialysis unit of Department of Medicine of Gian Sagar Medical College 
and Hospital, Ramnagar (Patiala), during the study period of 3 years 
(December, 2012 - December, 2015), were enrolled in the study. Each 
patient was considered only once for the study. Both men and women 
were included in this study.
Method of collection of data
The study was started after obtaining proper approval from the 
Institutional Research Ethics Committee. Patients were selected based 
on the inclusion and exclusion criteria. Approach to a patient began 
by taking informed consent, after proper medical examination. The 
detailed medical history as well as baseline demographic data such as 
age (yrs.), gender (M/F), weight (kg), height (cm), body mass index, 
religion, educational status (literate/illiterate), and environmental 
status (urban/rural) were recorded as per pro forma. Dietary history 
of the patients was obtained. Detailed history regarding the intake of 
phosphate binders, both calcium based and non-calcium based, and 
Vitamin D analogs was taken.
Blood sample was collected for laboratory investigations (such as 
serum calcium, serum phosphorous, serum alkaline phosphatase, 
serum iPTH, serum albumin, blood urea, serum creatinine, and 
hemoglobin). Blood samples were collected with aseptic precautions 
after obtaining informed consent from the patients. 5 ml of blood 
was taken from the antecubital vein of the patients under full aseptic 
conditions. Upon clotting, serum was separated out for the estimation 
of biochemical parameters. All the laboratory parameters were done on 
fully automated equipment, standardized in Gian Sagar Hospital.
Normal values of serum calcium (corrected for albumin) and phosphate 
were defined as 8.5-10.5 mg/dl and 2.5-4.5 mg/dl, respectively. 
PTH level >300 pg/ml (2 times the upper limit of the assay) was labeled 
as hyperparathyroidism (high bone turnover). The detailed data related 
to CKD-MBD were collected in pro forma and fed into custom-built 
database. Observations and results were compiled at the end of the 
study. The control of CKD-MBD was assessed in the backdrop of the 
KDIGO guidelines.
Statistical analysis
All the demographic and laboratory parameters were analyzed using 
Statistical Package for Social Sciences package version 17.0. Descriptive 
statistics such as range, mean, and standard deviation were used to 
describe continuous variables while numbers and percentages were 
used to present discreet variables. Chi-square test and analysis of 
variance (ANOVA) with post-hoc tukey’s HSD tests were used to test the 
association between clinical and laboratory parameters, and Pearson’s 
coefficient of correlation was used to assess the inter-relationship 
between various examined laboratory markers. The result was 
statistically significant when p<0.05.
RESULTS AND DISCUSSION
CKD-related MBD (CKD-MBD) is a worldwide challenge in hemodialysis 
patients [9]. CKD is characterized by the decline of kidney function 
within long period [10]. The decline of kidney function causes a 
range of complications including metabolic abnormalities, endocrine 
complications, and increased risk of cardiovascular diseases. These 
complications, if not managed appropriately, may implicate on the 
prolonged length of stay in the hospital and increased mortality rate [7,11].
The mineral and endocrine functions disrupted in CKD are critically 
important in the regulation of both initial bone formation during growth 
(bone modeling) and bone structure and function during adulthood 
(bone remodeling) [5]. As a result, bone abnormalities are found almost 
universally in patients with progressive loss of renal function in CKD 
which necessitates the eventual use of dialysis (stage 5D) [5].
The present study was a hospital-based, cross-sectional, observational 
study. The study population of 330 patients comprised adults, mainly 
illiterate (54.5%) predominantly belonging to the rural (66.4%) strata 
and Sikh community (62.7%), with a mean age of 52.67±15.05 years 
(range: 25-98 years) (Table 1), of whom most patients were taking 
vegetarian diet (58.2%).
In the present study, out of 330 patients, 159 patients were between 
the age group of 41-60 years, which suggests that incidence of CKD 
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increases with advanced age may be because of the ignorance regarding 
regular medical checkup (Table 2).
The mean age of our study population was almost similar to other 
Indian studies like that of Agarwal et al. [12] (42±13 years) and Prasad 
and Murthy [13] (49.3 years with range 17-80) and Valson et al. [14] 
(46.6±13.4 years).
However, higher mean age was reported in a Western study 
(74±15 years) by Craver et al. [15] and by Szeto et al. [16] (60±12 years).
Male preponderance in the present study (65.2%) (Table 1) was 
observed with the study having 215 males and 115 females. One of the 
main reasons for these differences in gender of patients may be that, 
in India, more male patients visit hospitals than females because of 
female health negligence mainly in rural areas due to male priority or 
may be because of male dominance and due to financial constrains for 
treatment.
Males made up the majority of the CKD patients with 70.6% similar to 
what was reported in other studies [17-19].
Another study from Pakistan by Hussain et al. [20] also found male 
predominance with the mean age of the patients in their study as 
58±16.6 years.
The predominant probable causes of CKD in our patients were as 
follows:
• Diabetes mellitus in 51.8%
• Drug-induced in 27.6%
• Hypertension in 14.5%
• Obstructive uropathy in 6.1% (Table 3).
Similar observations was made by Prasad and Murthy [13], who 
reported the cause of CKD as diabetic nephropathy in 38% of 
patients, hypertensive nephropathy in 28% of patients, chronic 
glomerulonephritis in 24% of patients, and obstructive uropathy in 6% 
of the patients.
Vhora et al. [21] observed that out of 60 CKD patients, 55% had 
hypertension and diabetic nephropathy together.
In a 10-year study of 368 patients with CKD in Nigeria, the etiology of 
renal failure was undetermined in 62%, and of the remaining patients 
whose etiology was ascertained, hypertension accounted for 61%, 
diabetes mellitus for 11%, and chronic glomerulonephritis for 5.9% [22].
In our study, drug-induced was the second common cause of renal 
failure in CKD patients (Table 3), ascertained with the help of medical 
history and patient’s records, which may be because of injudicious use 
of non-steroidal anti-inflammatory drugs in the treatment of any kind 
of pain, leading to side effects on renal functioning.
In the clinical profile of the present study, the most commonly reported 
symptoms were pruritus (6.1%), pedal edema (40.6%), and proximal 
muscle weakness (13.9%). In addition, bone pain and bone fracture 
were found in mild proportion, i.e., 19.1% and 4.8%, respectively 
(Table 3). Radiological findings revealed features suggestive of bone 
fracture on the basis of recent medical history/records. In the present 
study, majority of clinical symptoms related to CKD-MBD were found 
absent in CKD patients undergoing dialysis, reinforcing the fact that 
CKD-MBD is a clinically silent disease.
Our results were in accordance with the observations of Valson 
et al. [14] who reported similar clinical symptoms such as bone pain 
(33.5%), proximal muscle weakness (26.2%), and pruritus (25.5%), 
but in high percentage as compared to our findings.
The results of our study also revealed that bone pain was significantly 
associated with iPTH levels (both low and high level) (χ2=6.631 and 
p=0.036) (Table 4). It was observed that the percentage of CKD patients on 
hemodialysis of bone fracture was slightly more in hyperparathyroidism 
group (46.7%) as compared to hypoparathyroidism and normal 
parathyroidism (40.05 and 13.3%, respectively). This difference was 






Female 115 (34.8) 25 85 52.15±14.48
Male 215 (65.2) 25 98 52.95±15.36
Total 330 (100.00) 25 98 52.67±15.05
VS: Versus, SD: Standard deviation
Table 2: Age‑wise distribution






Table 3: Clinical characteristics of the study patients
Clinical characteristics of 
patients
Number of dialysis patients 
n=330 (%)
Probable cause of CKD
















Intake of phosphate binders
Not used 250 (75.8)
Used 80 (24.2)


















Eyes (redness, watery, or irritation)
Absent 286 (86.7)
Present 44 (13.3)
CKD: Chronic kidney disease, %: Percentage, n=330
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not statistically significant (χ2=1.372, P=0.503) (Table 5) although the 
incidence found for fracture was very low, only 5% (Table 3). PTH was 
also significantly associated with other physical symptoms such as 
proximal muscle weakness and eye problem (P=0.016 and P=0.001, 
respectively) (Tables 6 and 7). p<0.05 (if P is less than 0.05) was 
considered statistically significant.
iPTH level is directly linked with phosphorous and total alkaline 
phosphatase (tALP) laboratory parameters with significant p 
value (P=0.032 and P=0.035, respectively) as was proved with 
the ANOVA test of three intergroup comparisons of iPTH level 
that hyperparathyroidism and normal parathyroidism were more 
significantly associated with tALP level (P=0.002 and P=0.003, 
respectively) as compared to hypo-parathyroidism (P=0.987) 
(Table 8). Positive relationship was also found between iPTH and 
tALP levels (r=0.226, P=0.000) with Pearson’s correlation coefficient 
testing (Table 9).
Alterations in biochemical profile: MBD among CKD patients 
undergoing hemodialysis
In the biochemical profile, the target levels for corrected calcium 
(corrected for serum albumin), phosphorus, calcium × phosphorus 
(Ca × P) product, and iPTH levels should be maintained as recommended 
in the KDIGO guidelines for preventive MBD in CKD patients.
However, in the present study, it was observed that alterations in 
biochemical profile were common in hemodialysis patients. Only a 
small proportion of patients adhered to the targets. Proportion of the 
CKD patients who were out of the target range was as follows:
• 73.8% for iPTH (target range: 100-300 pg/ml).
• 55.8% for corrected serum calcium (target range: 8.5-10.5 mg/dl).
• 63.0% for phosphorus (target range: 2.5-4.5 mg/dl) and
• 50.0% patients for tALP (target range: 60-170 IU/L) were out of the 
target range (Fig. 1).
These results in our study indicated that most of the hemodialysis 
patients reported levels for biochemical profile which were outside the 
recommended range as per the KDIGO guidelines.
The percentage of patients, who were in the recommended range, was 
less than that obtained in other studies [22,23].
The inability of the CKD patients to achieve the above-said target range 
may be explained by many factors.
Implementing different modalities for regulation of calcium, 
phosphorus, and iPTH levels in Indian population is as follows:
• Patients were using calcium-based phosphate binders only (such as 
calcium acetate or calcium carbonate) in our center as compared to non-
calcium-based phosphate binders (such as sevelamer hydrochloride, 
or lanthanum carbonate, which is widely used in the USA and Europe 
for the treatment of hyperphosphatemia in patients with CKD [24,25].
• Moreover, in our study, only 24.2% of the CKD patients were using 
these binders (calcium-based phosphate binders).
• Though calcimimetic agent (cinacalcet HCl) [26] along with Vitamin D 
analogs may be used for controlling PTH secretion with minimal 
hypercalcemia and hyperphosphatemia [27], it was not advocated 
in our center.
In addition to this, the results of these tests are also influenced by 
food intake, adherence to and the timing of drug intake and dietary 
modifications, and differences in assay methods. This has also been 
documented in updated KDIGO guidelines 2016 [28].
In the current study, the laboratory profile in CKD patients was as 
follows:
Table 4: Association of PTH with bone pain




Absent 64 (29.9) 60 (28.0) 90 (42.1) 214
Present 24 (49.0) 9 (18.4) 16 (32.7) 49
Total 88 (33.5) 69 (26.2) 106 (40.3) 263
χ2=6.631, df(degree of freedom)=2, P(Probability)=0.036, significant, 
iPTH: Intact parathormone
Table 5: Association of PTH with bone fracture




Absent 82 (33.1) 67 (27.0) 99 (39.9) 248
Present 6 (40.0) 2 (13.3) 7 (46.7) 15
Total 88 (33.5) 69 (26.2) 106 (40.3) 263
iPTH: Intact Parathormone, χ2=1.372, df=2, p=0.503, not significant





Absent 69 (30.3) 64 (28.1) 95 (41.7) 228
Present 19 (54.3) 5 (14.3) 11 (31.4) 35
Total 88 (33.5) 69 (26.2) 106 (40.3) 263
iPTH: Intact parathormone, χ2=8.220, df=2, p=0.016, significant
Table 7: Association of PTH with eye problem
Eye problem PTH level Total
<100 100‑300 >300
Absent 67 (29.4) 65 (28.5) 96 (42.1) 228
Present 21 (60.0) 4 (11.4) 10 (28.6) 35
Total 88 (33.5) 69 (26.2) 106 (40.3) 263
iPTH: Intact Parathormone, χ2=13.252, df=2, p=0.001, significant, The analyzed 
iPTH data (total number of dialysis patients=263) were based on iPTH 
measurements, iPTH: Intact parathormone
Table 8: Association of PTH with tALP
PTH level N tALP
mean±SD
ANOVA# Comparison p#
A. <100 88 200.83±130.06 F=8.032;
p=0.000;
NS
A versus B 0.987NS
B. 100-300 69 191.79±141.38 A versus C 0.002NS
C. >300 106 377.70±540.86 B versus C 0.003NS
tALP: Total alkaline phosphatase, SD: Standard deviation, ANOVA: Analysis 
of variance. N: Number of dialysis patients #One-way ANOVA with post-hoc 
Tukey’s HSD; NS: p>0.05, not significant
Fig. 1: Biochemical profile of chronic kidney disease patients 
achieving Kidney Disease Improving Global Outcomes target levels
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• Hyperparathyroidism in 40.3%
• Hyperphosphatemia in 62.1%
• Hypocalcaemia in 50.6%
• Elevated tALP level in 49.4% of the patients (Table 10).
Statistically, a negative but significant correlation exists between corrected 
calcium and phosphorus (P=0.05 level of confidence interval). Calcium 
and phosphate show weak insignificant relationships with iPTH (Table 9).
The majority of hemodialysis patients had highly elevated serum PTH 
and phosphorus levels that suggest that some of the patients had severe 
secondary hyperparathyroidism.
Considering the fact, it was reported that impaired phosphate 
excretion, with the resulting hyperphosphatemia, is one of the 
earliest consequences of chronic renal failure. Hyperphosphatemia, 
in turn, plays an important role in the development of secondary 
hyperparathyroidism [29,30]. Moreover, phosphate retention leads to 
a decrease in serum-free calcium levels (hypocalcaemia), which in turn 
stimulates PTH secretion [31,32].
Similar to the present study, Okoye et al. [8] concluded that the prevalence 
of various mineral bone disease abnormalities was 70% of hyper-
phosphatemia and 85% of hyper-parathyroidism among the patients. 
Vhora et al. [21] reported hyperparathyroidism in 95% of CKD patients.
However, in these studies, the prevalence of hyperparathyroidism was 
much high as compared to our study.
Agarwal et al. [33] described hypocalcemia in 49.6% 
and hyperphosphatemia in 41.8% of CKD-5 patients and 
hyperparathyroidism in 39.4% of patients with CKD stage 5. He defined 
hyperparathyroidism (iPTH >300 pg/mL in stage 5 CKD) by using 
the K/DOQI guidelines 2002 [34].
Short of a bone biopsy, biochemical tests such as tALP or intact PTH can 
be used to evaluate bone disease.
Controlling PTH levels prevents damage to bones. In general, overactive 
parathyroid glands are controllable with a change in diet. Almost all foods 
contain phosphorus, but it is especially high in milk, cheese, peas, nuts, 
and peanut butter. Therefore, reducing dietary intake of phosphorus is 
one of the most important steps in preventing bone disease.
CONCLUSION
we showed in the present study that disorders of mineral metabolism 
are common in hemodialysis patients and that only a small proportion 
adheres to the targets as advised in the KDIGO guidelines for bone 
metabolism and disease in CKD. We demonstrated that these disorders 
are associated with important negative clinical outcomes, such as 
increased all-cause lack survival, more muscle and bone problems. 
Our findings, therefore, support a strict control of mineral metabolism 
in dialysis patients. We would like to emphasize the importance 
of educating and stimulating dialysis patients to achieve optimal 
adherence to the treatment regimens and dietary recommendations. 
A renal dietician can help develop a dietary plan to control phosphorus 
levels in the blood. Along with it, the use of phosphate-binding agents 
is a must. The aim of the treatment must be control of phosphate 
retention, maintaining serum calcium concentration within the normal 
range (standard), with avoidance of hypercalcemic episodes and 
prevention of excess PTH secretion.
Further research and progress in this area are required to establish 
a more rational approach with a view toward improving patient 
outcomes.
Table 9: Correlation
Age iPTH Corrected _calcium Serum phosphorus level t‑ALP
Age
r = 1 0.041 0.072 0.037 0.049
p = 0.506 0.191 0.499 0.375
iPTH
r = 0.041 1 0.120 −0.060 0.226**
p = 0.506 0.053NS 0.335NS 0.000
Corrected calcium
r = 0.072 0.120 1 −0.149** −0.034
p = 0.191 0.053NS 0.007* 0.535
Serum phosphorus level
r = 0.037 −0.060 −0.149** 1 −0.040
p = 0.499 0.335NS 0.007* 0.473
t-ALP
r = 0.049 0.226** −0.034 −0.040 1
p = 0.375 0.000 0.535 0.473
**Correlation is significant at the 0.01 level (two tailed). *correlation is significant at the 0.05 level (two tailed) r: Pearson’s correlation coefficient, P=Probability; NS(Not 
Significant) when P≥0.05,*(Significant)when P <0.05., *p<0.05, significant
Table 10: Laboratory parameters in CKD patients undergoing 
hemodialysis






Serum iPTH level (pg/ml) <100 88 (33.5)
100-300 69 (26.2)










More than 4.5 205 (62.1)




More than 170 163 (49.4)
Blood urea level (mg%) <15 3 (0.9)
15-45 3 (0.9)
More than 45 324 (98.2)
Serum creatinine level (mg%) 0.6-1.4 1 (0.3)
More than 1.4 329 (99.7)
Serum albumin level (g%) <3.5 200 (60.6)
3.5-5.5 130 (39.4)
Hemoglobin level (g%) <12 323 (97.90)
12-16 7 (2.1)
*Corrected calcium is calculated by the following formula:- {(4-patient 
albumin)*0.8+patient calcium level}:[4=normal albumin range]
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Recommendations
1. Awareness of CKD and KDIGO guidelines must be raised among 
renal physicians, the staff dealing with hemodialysis patients, and 
the patients.
2. Controlling PTH levels prevents damage to bones. Usually, overactive 
parathyroid glands are controllable with a change in diet, dialysis 
treatment, or medication.
3. Studies should be done to look into the role of serum levels of 
Vitamin D in CKD-MBD among our dialysis unit.
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